Quantcast
Last updated on April 18, 2014 at 10:25 EDT

Latest Somatic hypermutation Stories

2014-04-03 08:29:54

Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued US Patent #8,685,897 broadly covering a novel approach to antibody humanization using somatic hypermutation. Leveraging key advantages of AnaptysBio's...

2014-03-13 08:28:19

SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company. Under the terms of the agreement, AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody...

2013-12-17 08:29:17

SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the initiation of an antibody development program with Momenta Pharmaceuticals, Inc. focused on the development of novel antibodies against a therapeutically relevant target. Under this agreement, Momenta will pay an upfront fee to AnaptysBio in exchange for an option to acquire antibodies generated by AnaptysBio using its SHM-XEL platform against a specific...

2013-10-17 08:28:49

Expands patent portfolio to broadly protect antibody generation methodologies utilized by AnaptysBio's SHM-XEL platform SAN DIEGO, Oct. 17, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering its proprietary ABELmAb((TM)) libraries. Once issued, the allowed claims will broadly protect the...

2013-10-08 10:38:51

Researchers develop a first-of-its-kind mathematical model for the biological process that keeps your immune system working Scientists at USC have created a mathematical model that explains and predicts the biological process that creates antibody diversity – the phenomenon that keeps us healthy by generating robust immune systems through hypermutation. The work is a collaboration between Myron Goodman, professor of biological sciences and chemistry at the USC Dornsife College of...

2013-09-24 08:30:12

Recognized as one the most promising private biotechnology companies in the industry SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced its selection by the editors of FierceBiotech as one of the Fierce 15 for 2013. This selection designates AnaptysBio as one of the most promising private companies in the biotechnology industry, and is based upon the Company's validated antibody technology...

2013-08-29 08:24:48

Proprietary PD-1 antibody to be combined with TIM-3 and LAG-3 antagonists SAN DIEGO, Aug. 29, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the expansion of its proprietary immunotherapy antibody portfolio to include multiple new combination therapies. Using its SHM-XEL platform, the Company has recently developed a proprietary anti-PD-1 antibody, known as ANB011, with key differentiating advantages over...

2013-05-16 08:21:03

SHM-XEL platform to generate high thermostability antibodies for biodefense applications SAN DIEGO, May 16, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense applications. Under the terms of AnaptysBio's contract with the Science and Technology Corporation, AnaptysBio will be responsible for...

2012-12-04 08:28:39

SAN DIEGO, Dec. 4, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the publication of a novel full-length antibody scaffold, applicable to the development of highly thermostable antibodies for therapeutic and diagnostic applications, in the journal of Protein Engineering, Design & Selection (PEDS). (Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO) Entitled "An integrated approach to extreme...

2012-10-18 07:25:54

SAN DIEGO, Oct. 18, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the issuance of Patent # 8,288,160 entitled "Activation Induced Deaminase (AID)" by the U.S. Patent and Trademark Office (USPTO). This patent, the 16(th) issuance in AnaptysBio's intellectual property portfolio, broadly covers the use of in vitro somatic hypermutation (SHM) in eukaryotic cells for the discovery and optimization of antibodies. Previously...